Sunovion Submits New Drug Application for Dasotraline to the FDA for the Treatment of Patients with ADHD

MARLBOROUGH, Mass.--(BUSINESS WIRE) August 31, 2017 --Sunovion Pharmaceuticals Inc. (Sunovion) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for dasotraline, a novel...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news